Related Experiment Video

Updated: Jul 13, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

Cardiovascular actions of the peroxisome proliferator-activated receptor-alpha (PPARalpha) agonist Wy14,643

Peter Zahradka1

  • 1Institute of Cardiovascular Sciences, Department of Physiology, University of Manitoba and Canadian Centre for Agri-food Research in Health and Medicine, St. Boniface General Hospital Research Centre, Winnipeg, MB, Canada. peterz@sbrc.ca

Cardiovascular Drug Reviews
|July 7, 2007
PubMed

Insights

Wy14,643, a PPARalpha activator, impacts cardiovascular function through direct cellular effects and indirect liver metabolism changes. This review explores its dual actions on heart and vessels, considering both PPARalpha-dependent and -independent pathways.

Area of Science:

  • Pharmacology
  • Cardiovascular Biology
  • Metabolic Regulation

Background:

  • Wy14,643 is a hypolipidemic agent known to activate peroxisome proliferator-activated receptor-alpha (PPARalpha).
  • PPARalpha plays a crucial role in lipid metabolism and has implications for cardiovascular health.
  • Understanding the cardiovascular effects of Wy14,643 is important given its metabolic actions.

Purpose of the Study:

  • To review the effects of Wy14,643 on the cardiovascular system.
  • To detail the specific cellular processes influenced by Wy14,643 in vascular and cardiac tissues.
  • To discuss the indirect effects of Wy14,643 on liver metabolism and their relevance to cardiovascular disease.

Main Methods:

  • Literature review focusing on studies investigating Wy14,643.
  • Analysis of cellular mechanisms in cardiovascular tissues.
  • Examination of liver metabolism and its link to cardiovascular outcomes.
  • Discussion of PPARalpha-dependent and -independent pharmacological actions.

Main Results:

  • Wy14,643 exerts direct effects on vascular and cardiac cellular processes.
  • Indirect modulation of liver metabolism by Wy14,643 influences circulating lipids.
  • Both PPARalpha-dependent and -independent mechanisms contribute to Wy14,643's pharmacology.

Conclusions:

  • Wy14,643 has multifaceted effects on the cardiovascular system.
  • Its impact involves direct cellular actions and indirect metabolic regulation.
  • Further research into PPARalpha-dependent and -independent pathways is warranted.

More Related Videos

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells07:22

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Published on: March 28, 2013

Related Concept Videos

Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...